US contract research organisation (CRO) Capsugel has expanded its product portfolio into lipid-based formulations.
The New Jersey company, which Pfizer sold for $2.4bn in 2011 to investment firm KKR, has announced the launched of its Dosage Form Solutions (DFS) unit.
The CRO will have operation sites in the US, Europe and Asia and aims to leverage the firm’s proprietary technology platforms of lipid-based formulations and targeted release capsule formulation, along with its R&D capabilities and commercial manufacturing infrastructure to develop and manufacture products for customers.
“With the launch of the new DFS business unit, Capsugel builds on its heritage of delivering innovative, quality products and services in hard capsules, by advancing our expertise in product formulation and commercial finished product manufacturing,” said Capsugel’s president and CEO Guido Driesen.
“DFS is well-positioned to help address our customers’ most pressing dosage form challenges of existing and new nutritional and pharmaceutical products.”
Amit Patel, who spent nearly 10 years at Dr Reddy’s Laboratories, has been appointed to lead the DFS team.
“Continuing to innovate and develop cutting-edge healthcare products is essential to maximising the potential of the industry,” Patel said.
“The DFS business unit uses our proprietary technology platforms to help bring improved products to the market faster for our customers.
“The platforms can enable various solid oral dosage product improvements including bioavailability enhancement, optimal dosing for potent APIs, controlled release, stability improvement and taste masking.”
The business unit aims to develop products for leading and emerging speciality, branded and generic pharmaceutical customers, including companies in consumer health and nutritional segments.